

## Pharmacokinetic interactions between antiepileptic drugs

PHILIP N. PATSALOS

Institute of Neurology, University College London, The National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont St Peter, Bucks

---

Classically, a drug interaction is regarded as a modification of the effect of one drug by prior or concomitant administration of another. Interactions can be divided into two broad types, namely pharmacokinetic or pharmacodynamic. Pharmacokinetic interactions occur as a consequence of an effect at the site of drug absorption, plasma protein binding, metabolism or elimination and are associated with changes in blood concentrations (levels). Pharmacodynamic interactions occur as a consequence of an effect at the site of action of a drug, are not associated with any change in blood concentrations and are concluded by default.

Commonly, drug interactions have been discovered as a result of unexpected changes in the clinical status of patients upon addition or withdrawal of a drug from existing medication. A clinically significant drug interaction can be defined as one that results in the need to adjust dosage regimens in the majority of patients. However, the end result in individual patients also needs to be considered. For example, a modest or even marked elevation of a low plasma antiepileptic drug (AED) concentration consequent to an interaction may merely improve seizure control, and a small elevation of a nearly toxic concentration may precipitate toxicity. Similarly, a marked interaction in an unusually susceptible individual receiving drug polytherapy that causes little change in the majority of patients is equally significant.

Because there has been a major impetus in the last few years with regard to newly licensed AEDs, with the introduction of ten new AEDs worldwide, it is perhaps useful to consider interactions separately. Table I therefore shows, for the long-established and generally available AEDs, the expected changes in plasma concentrations when an AED is added to a concomitant AED regimen. Table II shows the expected changes in plasma concentrations of these drugs when one of the newly licensed AEDs is co-prescribed. The expected changes in plasma concentrations of a newly licensed AED when a generally available AED is added are shown in Table III. As clinical experience with these new AEDs increases it is likely that more drug interactions will be reported. It should be noted that, in addition, pharmacokinetic interactions could occur between AEDs and drugs used for the treatment of unrelated medical conditions and indeed with over-the-counter medications.

The pharmacokinetic interactions that are most significant clinically can be attributed to interactions at the metabolic level, and the best examples relate to inhibition or induction of the hepatic monooxygenase enzyme system (cytochrome P450, CYP) involved in drug metabolism. Induction involves the synthesis of new enzyme, and requires protein synthesis. Consequently, it may take many days before induction is complete and results in an increased drug metabolism, reduced plasma concentrations and an attenuated pharmacological effect (if no active metabolite is present). The process goes in reverse when the inducer is withdrawn with an increase in plasma concentrations of the target drug and hence an increased potential for toxic side effects.

Commonly, inhibition results from competition between drugs for the same active site on an isoenzyme of CYP, while induction involves production of more isoenzyme and therefore more binding sites. Circulating concentrations of the inhibited drug increase to a new steady state between four and six half-lives after the interaction has begun. Consequently, potential pharmacological effects will occur quickly if a drug has a short half-life, and more slowly if it has a long half-life. The minimum elapsed-time for maximum potentiation is: carbamazepine 4 days; ethosuximide 12 days; phenytoin 14 days; phenobarbitone 20 days; and valproate 3 days.

Of the AEDs illustrated in Table I, four (carbamazepine, phenytoin, primidone and phenobarbitone) are potent enzyme inducers. Valproate is a potent inhibitor. Phenytoin has some rather unique characteristics in that in addition to being an enzyme inducer, it is only loosely bound to CYP isoenzymes. It also exhibits saturation metabolic characteristics making it particularly susceptible to inhibitory interactions. Of the newly licensed AEDs (Tables II and III), gabapentin, lacosamide, levetiracetam and pregabalin uniquely do not appear to affect the concentrations of other AEDs, and are not themselves affected by other AEDs. In contrast eslicarbazepine acetate, lamotrigine, felbamate, oxcarbazepine, tiagabine, topiramate and zonisamide are associated with numerous clinically significant interactions.

Finally, in the past few years, interactions relating to the selective inhibition of the metabolism of carbamazepine to its epoxide metabolite, or subsequent metabolism of the epoxide, have been described. These may have considerable clinical significance, particularly since there is increasing evidence to suggest that the epoxide may contribute not only to the efficacy of carbamazepine but also to its toxicity. Carbamazepine epoxide plasma concentrations can be quadrupled in some patients by valproate, usually in the absence of changes in carbamazepine, and precipitating toxicity. With the more widespread availability of therapeutic monitoring of the epoxide, these interactions are increasingly being identified.

### **Further reading**

- HACHAD H, RAGUENEAU-MAJLESSI I, LEVY RH. New antiepileptic drugs: review on drug interactions. *Therapeutic Drug Monitoring* 2002; 24: 91-103.
- JOHANNESSEN LANDMARK C, PATSALOS PN, Drug interactions involving the new second- and third-generation antiepileptic drugs. *Expert Reviews in Neurotherapeutics* 2010; 10: 119-140.
- PATSALOS PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press 2005, Guildford, UK
- PATSALOS PN, BOURGEOIS BFD. The Epilepsy Prescriber's Guide to Antiepileptic Drugs. Cambridge University Press 2010, Cambridge, UK.
- PATSALOS PN, FROSCHER W, PISANI F, VAN RIJN CM. The importance of drug interactions in epilepsy therapy. *Epilepsia* 2002; 43: 365-385.
- PATSALOS PN, PERUCCA E. Clinically important interactions in epilepsy: General features and interactions between antiepileptic drugs. *Lancet Neurology* 2003; 2: 347-356.
- PATSALOS PN, PERUCCA E. Clinically important interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. *Lancet Neurology* 2003; 2: 473-481.

**Table I.** Expected changes in plasma concentrations when an antiepileptic drug (AED) is added to an existing AED regimen: long-established AEDs.

**EXISTING AED**

	<b>PB</b>	<b>PHT</b>	<b>PRM</b>	<b>ETS</b>	<b>CBZ</b>	<b>DZP</b>	<b>CZP</b>	<b>VPA</b>	<b>CLB</b>	
<b>A E D</b>	<b>PB</b>	AI	PHT↑↓	NCCP	ETS↓	CBZ↓	DZP↓	CZP↓	VPA↓	CLB↓ NDMC↑
	<b>PHT</b>	PB↑	AI	PRM↓ PB↑	ETS↓	CBZ↓	DZP↓	CZP↓	VPA↓	CLB↓ NDMC↑
	<b>PRM</b>	NCCP	PHT↑↓	AI	ETS↓	CBZ↓	DZP↓	CZP↓	VPA↓	CLB↓ NDMC↑
<b>A D D E D</b>	<b>ESM</b>	↔	↔	NA	-----	↔	NA	NA	VPA↓	NA
	<b>CBZ</b>	↔	PHT↑↓	PRM↓ PB↑	ETS↓	AI	DZP↓	CZP↓	VPA↓	CLB↓ NDMC↑
	<b>DZP</b>	NA	PHT↑↓	NA	NA	NA	-----	NA	NA	NA
	<b>CZP</b>	NA	PHT↑↓	NA	NA	CBZ↓	NA	-----	NA	NA
	<b>VPA</b>	PB↑	PHT↑↓	PB↑	ETS↑↓	CBZ-E↑	DZP↑*	NA	-----	NA
	<b>CLB</b>	PB↑	PHT↑↓	PB↑	NA	CBZ↓	NA	NA	VPA↑	-----

CBZ = carbamazepine; CBZ-E = carbamazepine epoxide; CLB = clobazam; CZP = clonazepam; DZP = diazepam; ETS = ethosuximide; NDMC = N-desmethyloclobazam; PB = phenobarbitone; PHT = phenytoin; PRM = primidone; VPA = valproic acid; NA = none anticipated; \* = free pharmacologically active concentration; AI = autoinduction; NCCP = not commonly co-prescribed, ↔ = No change.

↓ = an infrequently observed decrease in plasma concentration

↓ = a frequently observed decrease in plasma concentration

↑ = an infrequently observed increase in plasma concentration

↑ = a frequently observed increase in plasma concentration

**Table II.** Effect of newly licensed AEDs on plasma concentrations of the long-established AEDs.

		<u>EXISTING AED</u>					
		<u>PB</u>	<u>PHT</u>	<u>PRM</u>	<u>ETS</u>	<u>CBZ</u>	<u>VPA</u>
<b>A D D E D</b>	<b>VGB</b>	↔	PHT↓	↔	NA	↔	↔
	<b>LTG</b>	↔	↔	↔	↔	↔	↔
	<b>GBP</b>	↔	↔	NA	NA	↔	↔
	<b>TPM</b>	↔	PHT↑	↔	NA	↔	VPA↓
<b>A E D</b>	<b>PGB</b>	↔	↔	NA	NA	↔	↔
	<b>FBM</b>	PB↑↑	PHT↑↑	?	?	CBZ↓ CBZ-E↑	VPA↑↑
	<b>TGB</b>	↔	↔	↔	NA	↔	↔
	<b>OXC</b>	PB↑	PHT↑	?	?	CBZ↓	↔
	<b>LEV</b>	↔	↔	↔	NA	↔	↔
	<b>ZNS</b>	↔	PHT↑	↔	NA	CBZ↑↓↔	
	<b>LCM</b>	NA	↔	↔	NA	↔	↔
	<b>ESL-a</b>	↔	PHT↑	↔	↔	↔	↔

CBZ = carbamazepine; CBZ-E = carbamazepine epoxide; ESL-a = esliarbazepine acetate; ETS = ethosuximide; FBM = felbamate; GBP, = gabapentin; LCM = lacosamide; LEV = levetiracetam; LTG = lamotrigine; OXC = oxcarbazepine; 10-OH-OXC = 10, 11-dihydroxycarbamazepine; PB = phenobarbitone; PHT = phenytoin; PRM = primidone; PGB = pregabalin; TGB = tiagabine; TPM = topiramate; VPA = valproic acid; VGB = vigabatrin; ZNS = zonisamide; NA = none anticipated, ? = indicates an unknown effect; ↔ = No change.

↓: an infrequently observed decrease in plasma concentration  
 ↑: an infrequently observed increase in plasma concentration

⇓: a frequently observed decrease in plasma concentration  
 ⇑: a frequently observed increase in plasma concentration

**Table III.** Effect of the long-established AEDs on plasma concentrations of newly licensed AEDs.

		<u>EXISTING AED</u>											
		VGB	LTG	GBP	TPM	PGB	FBM	TGB	OXC	LEV	ZNS	LCM	ESL-a
<b>A D E D  A E D</b>	<b>PB</b>	↔	LTG↓	↔	TPM↓	↔	FBM↓	TGB↓	10-OH-OXC ↓	↔	ZNS↓	NA	?
	<b>PHT</b>	↔	LTG↓	↔	TPM↓	↔	FBM↓	TGB↓	10-OH-OXC ↓	↔	ZNS↓	↔	ESL↓
	<b>PRM</b>	↔	LTG↓	↔	TPM↓	NA	FBM↓	TGB↓	?	NA	ZNS↓	NA	?
	<b>ETS</b>	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	<b>CBZ</b>	↔	LTG↓	↔	TPM↓	↔	FBM↓	TGB↓	10-OH-OXC ↓	↔	ZNS↓	↔	ESL↓
	<b>VPA</b>	↔	LTG↑	↔	TPM↓	↔	↔	↔	↔	↔	ZNS↓	↔	?

CBZ = carbamazepine; CBZ-E = carbamazepine epoxide; ESL= eslicarbazepine; ESL-a = esliarbazepine acetate; ETS = ethosuximide; FBM = felbamate; GBP, = gabapentin; LCM = lacosamide; LEV = levetiracetam; LTG = lamotrigine; OXC = oxcarbazepine; 10-OH-OXC = 10, 11-dihydroxycarbazepine; PB = phenobarbitone; PHT = phenytoin; PRM = primidone; PGB = pregabalin; TGB = tiagabine; TPM = topiramate; VPA = valproic acid; VGB = vigabatrin; ZNS = zonisamide; NA = none anticipated, ? = indicates an unknown effect; ↔ = No change.

↓: an infrequently observed decrease in plasma concentration  
 ↑: an infrequently observed increase in plasma concentration

↓↓: a frequently observed decrease in plasma concentration  
 ↑↑: a frequently observed increase in plasma concentration